|
1
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
classification of tumors of the central nervous system: A summary.
Acta neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ostrom QT, Gittleman H, Farah P, Ondracek
A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C and Barnholtz-Sloan JS:
CBTRUS statistical report: Primary brain and central nervous system
tumors diagnosed in the United States in 2006–2010. Neuro Oncol. 15
(Suppl 2):ii1–ii56. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Darefsky AS, King JT Jr and Dubrow R:
Adult glioblastoma multiforme survival in the temozolomide era: A
population-based analysis of Surveillance, Epidemiology, and End
Results registries. Cancer. 118:2163–2172. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thakkar JP, Dolecek TA, Horbinski C,
Ostrom QT, Lightner DD, Barnholtz-Sloan JS and Villano JL:
Epidemiologic and molecular prognostic review of glioblastoma.
Cancer Epidemiol Biomarkers Prev. 23:1985–1996. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stupp R, Dietrich PY, Ostermann Kraljevic
S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G,
Miralbell R, et al: Promising survival for patients with newly
diagnosed glioblastoma multiforme treated with concomitant
radiation plus temozolomide followed by adjuvant temozolomide. J
Clin Oncol. 20:1375–1382. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wind JJ, Young R, Saini A and Sherman JH:
The role of adjuvant radiation therapy in the management of
high-grade gliomas. Neurosurg Clin N Am. 23247–258. (viii)2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Caruso C, Carcaterra M and Donato V: Role
of radiotherapy for high grade gliomas management. J Neurosurg Sci.
57:163–169. 2013.PubMed/NCBI
|
|
9
|
Zhen Y, Chunlei G, Wenzhi S, Shuangtao Z,
Na L, Rongrong W, Xiaohe L, Haiying N, Dehong L, Shan J, et al:
Clinicopathologic significance of legumain overexpression in
cancer: A systematic review and meta-analysis. Sci Rep.
5:165992015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin Y, Wei C, Liu Y, Qiu Y, Liu C and Guo
F: Selective ablation of tumor-associated macrophages suppresses
metastasis and angiogenesis. Cancer Sci. 104:1217–1225. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cancer Genome Atlas Research Network, ;
Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA,
Ellrott K, Shmulevich I, Sander C, Stuart JM, et al: The Cancer
Genome Atlas Pan-Cancer analysis project. Nat Genet. 45:1113–1120.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zheng LL, Zhou KR, Liu S, Zhang DY, Wang
ZL, Chen ZR, Yang JH and Qu LH: dreamBase: DNA modification, RNA
regulation and protein binding of expressed pseudogenes in human
health and disease. Nucleic Acids Res. 46:D85–D91. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brown CE, Alizadeh D, Starr R, Weng L,
Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J,
Simpson J, et al: Regression of glioblastoma after chimeric antigen
receptor t-cell therapy. N Engl J Med. 375:2561–2569. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mitchell DA, Batich KA, Gunn MD, Huang MN,
Sanchez-Perez L, Nair SK, Congdon KL, Reap EA, Archer GE,
Desjardins A, et al: Tetanus toxoid and CCL3 improve dendritic cell
vaccines in mice and glioblastoma patients. Nature. 519:366–369.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kaufmann JK and Chiocca EA: Glioma virus
therapies between bench and bedside. Neuro Oncol. 16:334–351. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hottinger AF, Pacheco P and Stupp R: Tumor
treating fields: a novel treatment modality and its use in brain
tumors. Neuro Oncol. 18:1338–1349. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stupp R, Taillibert S, Kanner AA, Kesari
S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink
KL, et al: Maintenance therapy with tumor-treating fields plus
temozolomide vs temozolomide alone for glioblastoma: A randomized
clinical trial. JAMA. 314:2535–2543. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ryu S, Buatti JM, Morris A, Kalkanis SN,
Ryken TC and Olson JJ; AANS/CNS Joint Guidelines Committee, : The
role of radiotherapy in the management of progressive glioblastoma:
A systematic review and evidence-based clinical practice guideline.
J Neurooncol. 118:489–499. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lutz ST, Jones J and Chow E: Role of
Radiation Therapy in Palliative Care of the Patient With Cancer. J
Clin Oncol. 32:2913–2919. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gallego O: Nonsurgical treatment of
recurrent glioblastoma. Curr Oncol. 22:E273–E281. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Arias-Lopez C, Lazaro-Trueba I, Kerr P,
Lord CJ, Dexter T, Iravani M, Ashworth A and Silva A: p53 modulates
homologous recombination by transcriptional regulation of the RAD51
gene. EMBO Rep. 7:219–224. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Quick QA and Gewirtz DA: An accelerated
senescence response to radiation in wild-type p53 glioblastoma
multiforme cells. J Neurosurg. 105:111–118. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem
cells promote radioresistance by preferential activation of the DNA
damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gorski DH, Beckett MA, Jaskowiak NT,
Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM,
Kufe DW, et al: Blockade of the vascular endothelial growth factor
stress response increases the antitumor effects of ionizing
radiation. Cancer Res. 59:3374–3378. 1999.PubMed/NCBI
|
|
25
|
Geng L, Donnelly E, McMahon G, Lin PC,
Sierra-Rivera E, Oshinka H and Hallahan DE: Inhibition of vascular
endothelial growth factor receptor signaling leads to reversal of
tumor resistance to radiotherapy. Cancer Res. 61:2413–2419.
2001.PubMed/NCBI
|
|
26
|
Hatanpaa KJ, Burma S, Zhao D and Habib AA:
Epidermal growth factor receptor in glioma: Signal transduction,
neuropathology, imaging, and radioresistance. Neoplasia.
12:675–684. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mukherjee B, McEllin B, Camacho CV,
Tomimatsu N, Sirasanagandala S, Nannepaga S, Hatanpaa KJ, Mickey B,
Madden C, Maher E, et al: EGFRvIII and DNA double-strand break
repair: A molecular mechanism for radioresistance in glioblastoma.
Cancer Res. 69:4252–4259. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liccardi G, Hartley JA and Hochhauser D:
Importance of EGFR/ERCC1 interaction following radiation-induced
DNA damage. Clin Cancer Res. 20:3496–3506. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang M, Kleber S, Roehrich M, Timke C,
Han N, Tuettenberg J, Martin-Villalba A, Debus J, Peschke P,
Wirkner U, et al: Blockade of TGF-β signaling by the TGFβ R-I
kinase inhibitor LY2109761 enhances radiation response and prolongs
survival in glioblastoma. Cancer Res. 71:7155–7167. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dungey FA, Caldecott KW and Chalmers AJ:
Enhanced radiosensitization of human glioma cells by combining
inhibition of poly(ADP-ribose) polymerase with inhibition of heat
shock protein 90. Mol Cancer Ther. 8:2243–2254. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu M, Shao GR, Zhang FX, Wu WX, Xu P and
Ruan ZM: Legumain protein as a potential predictive biomarker for
Asian patients with breast carcinoma. Asian Pac J Cancer Prev.
15:10773–10777. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Haugen MH, Boye K, Nesland JM, Pettersen
SJ, Egeland EV, Tamhane T, Brix K, Maelandsmo GM and Flatmark K:
High expression of the cysteine proteinase legumain in colorectal
cancer-implications for therapeutic targeting. Eur J Cancer.
51:9–17. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guo P, Zhu Z, Sun Z, Wang Z, Zheng X and
Xu H: Expression of legumain correlates with prognosis and
metastasis in gastric carcinoma. PLoS One. 8:e730902013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhu Q, Tang M and Wang X: The expression
of asparaginyl endopeptidase promotes growth potential in
epithelial ovarian cancer. Cancer Biol Ther. 18:222–228. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhu W, Shao Y, Yang M, Jia M and Peng Y:
Asparaginyl endopeptidase promotes proliferation and invasiveness
of prostate cancer cells via PI3K/AKT signaling pathway. Gene.
594:176–182. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Meng F and Liu W: Knockdown of legumain
suppresses cervical cancer cell migration and invasion. Oncol Res.
23:7–12. 2016. View Article : Google Scholar
|
|
37
|
Kalyana-Sundaram S, Kumar-Sinha C, Shankar
S, Robinson DR, Wu YM, Cao X, Asangani IA, Kothari V, Prensner JR,
Lonigro RJ, et al: Expressed pseudogenes in the transcriptional
landscape of human cancers. Cell. 149:1622–1634. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Johnsson P, Ackley A, Vidarsdottir L, Lui
WO, Corcoran M, Grandér D and Morris KV: A pseudogene
long-noncoding-RNA network regulates PTEN transcription and
translation in human cells. Nat Struct Mol Biol. 20:440–446. 2013.
View Article : Google Scholar : PubMed/NCBI
|
